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Cancer cells have been at the centre of cell metabolism research, but the metabolism of stromal and immune cells has
received less attention. Nonetheless, these cells influence the progression of malignant, inflammatory and metabolic
disorders. Here we discuss the metabolic adaptations of stromal and immune cells in health and disease, and highlight
how metabolism determines their differentiation and function.
S tromal cells are connective cells that support parenchymal cells.Aside from endothelial cells (ECs), which build blood vessels tosupply oxygen and nutrients1,2, other stromal cells include fibro-
blasts, whichmaintain the structural framework in tissues. Another class
of cells that maintains tissue homeostasis is immune cells. The immune
system collectively functions to protect tissues from infections and for-
eign antigens. Notably, several of these cell types not only contribute to
disease progression but also to therapy resistance3.
Cancer cells undergonumerousmetabolic adaptations; a result of onco-
genic transformation, gene mutations or altered expression of metabolic
enzymes4–7.Metabolismof stromal and immune cells has received less atten-
tion, yet they represent an abundant cell population in tissues and tumours,
even up to 80–90% in some desmoplastic tumours8. We focus on two types
of immune cells (T cells and macrophages) and two types of stromal cells
(ECs and fibroblasts), for which metabolism has been best characterized.
Emerging evidence indicates that metabolism not only co-determines their
differentiation and function, but also that metabolic changes in these cells
contribute to thepathogenesis of cancer,diabetes and inflammatorydiseases.
Vascular endothelial cells
ECs are quiescent for years, but when tissues are deprived of oxygen or
nutrients, they sprout to vascularize tissues.Vessel sprouting is ahighly coor-
dinated process, relying on a migrating endothelial ‘tip’ cell at the forefront
that guides thevessel sprout (but rarelyproliferates), andon trailingendothe-
lial ‘stalk’ cells elongating the sprout via proliferation1,9. Vascular endothelial
growth factor (VEGF) is a tip cell signal,whereasDelta-like 4 (DLL4)/Notch
signalling is a stalk cell signal. Tip versus stalk cell phenotypes are not pre-
determined cell fates, but are interchangeable. By competing for the tipposi-
tion, ECs continuously secure optimal fitness to lead the sprout. Although
many genetic signals regulate this process, the role of EC metabolism in
vessel sprouting has only recently been considered. We postulated that
this angiogenic switch requires a metabolic switch10.
Endothelial cells are glycolytic
ECs have immediate access to oxygen in the blood, but do not take advant-
age of its availability to adopt an oxidative metabolism. Instead, oxygen
consumption is lower and the mitochondrial volume fraction is smaller
than in oxidative cell types11. Also, inhibition of mitochondrial ATP pro-
ductionor stimulationofoxygenconsumptiondoesnot affect vessel sprout-
ing10. This is in line with reports that EC mitochondria serve a signalling
function via the production of pro-angiogenic reactive oxygen species
(ROS) rather than act as a bioenergetic power source12. Instead, ECs are
highly glycolytic,more so than other cell types, and generate up to 85%of
their ATP via glycolysis10 (Fig. 1a). In fact, their glycolytic rates are com-
parable to those in many cancer cells, known to have a high aerobic gly-
colytic metabolism10. ECs are glucose addicted, as glucose starvation or
treatmentwith the glucose analogue 2-deoxy-D-glucose induces cytotoxi-
city13. Although quiescent ECs require substantial glycolysis for homeo-
staticmaintenance, glycolysis is still increased (by twofold) when shifting
to proliferation10.
A recent report studied the role of glycolysis in vessel sprouting by
focusing on 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
(PFKFB3)10. Its kinase activity is 700-fold higher than its bisphosphatase
activity and favours the production of fructose-2,6-bisphosphate (F2,6BP),
anallosteric activatorofphosphofructokinase-1 (PFK1), itself a rate-limiting
enzyme of glycolysis (Fig. 1a). Inhibition of PFKFB3 reduces EC glycolytic
flux levels, but by nomore than 30–40%.Nonetheless, this is sufficient to
impair vessel sprouting in vitro and induce vascular hypobranching
in vivo10. Mechanistically, PFKFB3 deficiency in ECs reduces proliferation
of stalk cells, in agreement with reports that PFKFB3-driven glycolysis is
elevated in theG1 cell cycle phase in preparation for the S phase. PFKFB3-
driven glycolysis is also necessary for tip cell function (that is, migration)
and competitiveness by providing energy for the remodelling of the cyto-
skeleton. Indeed,whenECs form lamellipodia tomigrate, glycolytic enzymes
are relocated to theseprotrusions,where theybecomeassociatedwithF-actin.
This compartmentalization enhances local synthesis of ATP at the lead-
ing membrane ruffles in lamellipodia10.
Treatment of mice with a PFKFB3 blocker reduces glycolysis only par-
tially and transiently, yet impairs pathological angiogenesis, indicating that
ECs are sensitive to small changes in glycolysis14. More complete and sus-
tained inhibition of glycolysis by 2-deoxy-D-glucose impairs angiogenesis
but ismore toxic.Hence, partial and transient blockade of glycolysismay
provide a new paradigm for anti-angiogenic therapy.
There are several hypotheses attempting to explain why ECs prefer gly-
colysis even though sufficient oxygen is present for oxidative metabolism
(‘aerobic glycolysis’) and despite the fact that glucose oxidation is more
efficient in yieldingATP(only 2moles ofATPare generated via glycolysis
versus up to 36moles of ATP via glucose oxidation, per mole of glucose).
First, by minimizing oxygen consumption, quiescent ECs reserve more
oxygen for transfer to perivascular tissue cells. Second, ECs must vas-
cularize avascular tissues, where low oxygen levels would preclude oxid-
ative metabolism. Third, because of its high rate, glycolysis can generate
more ATP than oxidative phosphorylation (OxPhos) as long as glucose
availability is not limiting15. In fact, since interstitial oxygen levels drop
faster than glucose levels over a distance away from a blood vessel, ECs
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can continue to rely on anaerobic glycolysis16. ECs are also resistant to
hypoxia as long as glucose is available, but become sensitive to oxygen-
deprivation when glucose is limiting17. Finally, glycolytic intermediates
are used for anabolic generation of macromolecules and for redox control,
which are necessary for EC proliferation, migration and survival18. Aside
from their metabolic role, glycolytic metabolites (lactate) can stimulate
angiogenesis also as signalling molecules (Box 1).
Role of additional metabolic pathways in ECs
The role of other metabolic pathways in angiogenesis in vivo remains
less well defined (Fig. 1a). The pentose phosphate pathway (PPP), a side
pathway of glycolysis, promotes cell proliferation by producingNADPH
and ribose-5-phosphate, which are used for the synthesis of lipids, nu-
cleotides and amino acids (histidine). The PPP also provides protection
against oxidative stress by controlling redoxhomeostasis. Indeed,NADPH
is used to convert the oxidized form of glutathione (GSSG) to its reduced
form (GSH), a major antioxidant19.
Another fuel used by proliferating cells is L-glutamine (referred to as
glutamine), which has various metabolic fates, for example, oxidation of
glutamine-derived a-ketoglutarate (a-KG) for energy production, glu-
taminolysis followed by pyruvate recycling into the tricarboxylic acid
(TCA) cycle for continuedTCAcycling, reductive carboxylation for lipid
synthesis, or polyamine synthesis for mitogenesis (Fig. 1a). In line with
findings that blockade of mitochondrial ATP production does not affect
vessel sprouting10, the importance of glutamine oxidation for the pro-
duction of ATP in ECs is debated10,20. Nonetheless, glutamine metabol-
ism is essential, as inhibition of glutaminase decreases proliferation and
induces senescence of ECs21,22. ECs also use glutamine for the production
of ornithine, a precursor of polyamines23. The role of glutaminolysis and
reductive carboxylation in relation to vessel sprouting has not been studied
to date.
Fatty acids can also serve as fuel for energy production, such as in
oxidative cardiomyocytes. In metabolically stressed cancer cells, fatty
acid oxidation (FAO) is vital for their survival by generating ATP and
ensuring redox homeostasis (Fig. 1a)24. ECs also metabolize fatty acids
for ATP production, but like for glutamine oxidation, the importance of
FAO relative to glycolysis is debated20,25. Another role of FAO in ECs has
not been described yet. Notably, proliferative cells also synthesize lipids,
partly to form new membranes for cell division, to generate signalling
molecules or to modulate signalling26. For instance, cholesterol pro-
motes vessel sprouting by facilitating the formation of membrane lipid
rafts in ECs, necessary formembrane localization and signalling of the pro-
angiogenic VEGF receptor (VEGFR)-2 (ref. 27). Conversely, apolipopro-
tein-B lipoproteins, involved in cholesterol transport, impair angiogenesis
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Figure 1 | Endothelial cell metabolism. For all figures: important metabolic
pathways onto which cells rely are shown in colour; less critical or studied
pathways are shown in grey. a, Scheme of the metabolic pathways in a normal
EC. (i) ECs use glucose as primary source for energy production and are highly
glycolytic (blue). Only a minor fraction of glucose is oxidized in the TCA cycle
(orange). (ii) PFKFB3 is a regulator of glycolysis via conversion of F1,6BP to
F2,6BP, an activator of PFK1. (iii) The PPP generates NADPH for redox
homeostasis (purple). FAO generates acetyl-CoA (red) (iv), whereas glutamine
metabolism generates a-KG (green) (v), which are metabolized in the TCA
cycle (clockwise direction; orange). However, their importance versus
glycolysis is unclear (denoted by questionmarks). (vi) ECs also synthesize fatty
acids (FAS; pink). (vii) NOS converts arginine to nitric oxide (NO) and
citrulline, which is recycled to regenerate arginine (tan). Inset: proliferating ECs
have higher glycolysis than quiescent ECs; glycolysis is higher in tip than stalk
cells. b, Metabolic changes in ECs in diabetes. (i) High glucose levels impair the
PPP (tan), thereby loweringNADPHand elevatingROS levels. (ii) ROS reduces
glycolysis by inactivating GADPH. (iii) This increases the polyol pathway
flux (dark orange), leading to generation of ROS and toxic AGEs. (iv) The flux
of the hexosamine biosynthesis pathway (cyan) is also increased, resulting in
alteration of glycosylation. (v)GAP andDHAP are converted tomethylglyoxal,
leading to production of ROS andAGEs (olive). (vi) Excessmitochondrial ROS
generation inhibits GAPDH, leading to accumulation of GAP and DHAP and
reducing glycolysis. (vii) High glucose levels increase FAO at the expense of
glucose oxidation. (viii) Increased arginase levels reduce the availability of
arginine for the production of NO byNOS, which is uncoupled/less functional,
and produces superoxide that induces mitochondrial dysfunction (tan). 3PG,
3-phosphoglycerate; a-KG, a-ketoglutarate; Ac-CoA, acetyl-coenzyme A;
AGEs, advanced glycation end products; AR, aldose reductase; ARG, arginase;
ASL, argininosuccinate lyase; Asp, aspartate; ASS, argininosuccinate synthase;
Cit, citrate; CPT, carnitine palmitoyltransferase; DHAP, dihydroxyacetone
phosphate; eNOS, endothelial nitric oxide synthase; ETC, electron transport
chain; F1,6BP, fructose 1,6-bisphosphate; F2,6BP, fructose 2,6 bisphosphate;
F6P, fructose 6-phosphate; FA, fatty acid; FABP, fatty acid binding protein;
FAO, fatty acid oxidation; FAS, fatty acid synthesis; FATP, fatty acid transfer
protein; Fum, fumarate; G6P, glucose 6-phosphate; GAP, glyceraldehyde
3-phosphate; Glc, glucose; GlcN, glucosamine; Gln, glutamine; Glu, glutamate;
GLUT, glucose transporter; HBP, hexosamine biosynthesis pathway; Lac,
lactate; MCT, monocarboxylate transporter; NADPH, nicotinamide adenine
dinucleotide phosphate; NO, nitric oxide; OAA, oxaloacetate; OTC,
ornithine transcarbamylase; OxPhos, oxidative phosphorylation; PFK1,
phosphofructokinase-1; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-3; PPP, pentose phosphate pathway; Pyr, pyruvate; ROS,
reactive oxygen species; TCA, tricarboxylic acid.
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by upregulating the expression of an anti-angiogenic VEGF-trap (that is,
VEGFR-1) via unknownmechanisms28. Fatty acid synthesis is relevant for
angiogenesis, as its inhibition impairs capillary formation29.
The hexosamine biosynthetic pathway is a side branch of glycolysis,
which produces N-acetylglucosamine, an intermediate in N-linked and
O-linked glycosylation. As this pathway uses glutamine, glucose, acetyl-
CoA, uridine and ATP, it functions as a nutrient sensor. ECs use this path-
way to glycosylate key angiogenic molecules, such as VEGFR-2, Notch and
others. Interfering with glycosylation has contextual effects, but can none-
theless impair angiogenesis30.
Dysregulated metabolism of ECs in diabetes
EC dysfunction
The endothelium modulates vascular tone, structure and homeostasis.
Maladaptivemetabolic changes inECs contribute to vascular complications
indiabetes. Functionaldisruptionof the endotheliumin type2diabetes is an
early event that promotes atherosclerosis and microangiopathy2. Notably,
ECs arehighly glycolytic at normalplasmaglucose levels (5.5mM), but high
glucose levels (25mM) render glucose metabolism of ECs maladaptive. In
an EC line, high glucose increases FAOwhile decreasing glucose oxidation,
a contextual finding requiring confirmation in primary ECs31. Various
metabolic changes have been proposed to promote vascular complications
in diabetics, largely by increasing oxidative stress due to generation of
various types of ROS (such as superoxide (O2
2N) and hydrogen peroxide
(H2O2)) and reactive nitrogen species (including nitric oxide (NO))
(Fig. 1b). First, high glucose levels cause mitochondrial dysfunction and
increase the production of ROS via protein kinase C-dependent activation
of NADPH-dependent oxidases, a major source of ROS in diabetic ECs32.
Second, ROS detoxification is impaired in ECs, as high glucose decreases
the production of NADPH for redox control by inhibiting glucose-6-
phosphate-dehydrogenase (G6PD), a rate-limitingPPPenzyme.Third,ROS
indirectly inactivate the glycolytic enzyme GAPDH, which lowers gly-
colysis33. As a result of the reduced PPP and glycolytic flux, more glucose
is shunted to the polyol pathway, which ECs use when exposed to high
glucose in excess of what the glycolytic pathway can handle. Here, aldose
reductase (AR) reduces glucose to sorbitol, which is further converted to
fructose34. AsAR converts NADPH toNADP1, activation of this pathway
depletes NADPH stores, which are necessary to maintain GSH levels for
redoxhomeostasis, and thuspromotesROSaccumulation. Sorbitol-derived
fructose also generates the highly reactive 3-deoxyglucosone, which pro-
motes the formation of advanced glycation end products (AGEs). Such
glycated proteins and lipids contribute to vascular complications through
formation of crosslinks between molecules in the basement membrane
that alter the extracellular matrix. They also engage the receptor for AGEs
(RAGE) on ECs, which induces vascular inflammation, leakage and further
ROS production35.
Fourth,ROSaregeneratedwhenmethylglyoxal is formedfromtheglycolytic
metabolites dihydroxyacetone phosphate (DHAP) and glyceraldehyde-
3-phosphate (GAP).The generationofmethylglyoxal is enhanced inhyper-
glycaemicECsbecausehighglucose levels increase the formationof fructose
(see above), which is metabolized to fructose-6-phosphate, and in turn to
GAP and DHAP36. Production of methylglyoxal is also increased via inac-
tivation of GAPDH by ROS, which again increases GAP and DHAP levels
(Fig. 1b). Elevatedplasma levels ofmethylglyoxal indiabetic patients exacer-
bate ECdysfunction, and induce the formation ofAGEs, oxidative stress and
EC apoptosis, in addition to impairing vascular reactivity, altogether contrib-
uting to vascular complications and hypertension in diabetics37.
Fifth, high glucose levels impair endothelial nitric oxide synthase (eNOS)
activity through increased O-linked glycosylation. They also uncouple
eNOS, which instead of generatingNO, now producesO2
2N. By inhibiting
cytochrome c oxidase in the mitochondrial electron transport chain, these
reactive species promote EC dysfunction38,39 (Fig. 1b). High glucose levels
uncouple eNOS by increasing the levels of arginase, the enzyme that con-
sumes L-arginine (referred to as arginine) necessary for the generation of
NO (Fig. 1b).
Finally, ROS generated from high glucose exposure impairs angio-
genesis via ligand-independent phosphorylation ofVEGFR-2, leading to
its reduced availability at the cell surface40. This was verified in an ob/ob
mouse model of diabetes, and the effect was reversed by treatment of dia-
beticmice with the antioxidantN-acetyl-L-cysteine40. However, it should be
cautioned that the precise contribution of oxidative stress to the develop-
mentof vascular complications indiabetes remainsdebated.Also, despite all
of this preclinical evidence, clinical antioxidant trials have not yielded over-
whelmingly improved outcomes, highlighting the need for further study of
these metabolic pathways41. Furthermore, studies onmetabolic changes in
diabetic ECs using metabolic tracing are warranted.
Ocular neovascularization
Diabetes impairs revascularization of ischaemic, inflamed and wounded
tissues and impedes re-endothelialization of damaged vessels (such as
after percutaneous coronary interventions), but also causes retinopathy
characterized by overgrowth of leaky vessels inducing blindness2. Vessel
BOX 1
Signalling effects of metabolites
and metabolic enzymes
Endothelial cells
Lactate, produced by cancer cells, promotes tumour angiogenesis via
mechanisms independent of its role in glycolysis. By inhibiting the
oxygen-sensing prolyl hydroxylase 2 (PHD2), lactate activates the
hypoxia-inducible transcription factor HIF-1a in cancer cells and
upregulates angiogenic signals97. Via the same mechanism, lactate
triggers IkBa degradation, thereby stimulating an autocrine pro-
angiogenic NF-kB/IL-8 pathway98. Furthermore, lactate activates the
receptor tyrosine kinases AXL, TIE2 and VEGFR-2 in a ligand-
independent manner99. In agreement, perturbing lactate influx in ECs
by blocking the monocarboxylate transporter-1 (MCT1) inhibits
tumour angiogenesis21. Interestingly, metabolic enzymes may also
affectpost-translationalmodificationof targets. For instance,EC lossof
fatty acid synthase (FASN) impedes angiogenesis by reducing
palmitoylation of VEGFR-2 and eNOS, which impairs their plasma
membrane targeting and activation100.
Immune cells
Several metabolites have a signalling role in immune cells. For
instance, high levels of the adenylate AMP in nutrient-poor conditions
activate AMPK and control a metabolic checkpoint in Tcells by acting
asabrakeon immunecell expansionwhenenergy supplies arepoor55.
Another example is a-KG, which is a substrate for a-KG-dependent
dioxygenases, such as PHDs, DNA hydroxylases and histone
demethylases, whereas the TCA cycle intermediates fumarate and
succinate inhibit PHDsviaproduct-mediated inhibition. This stabilizes
HIF-1aand inducesa transcriptionalprogramthat inducesashift from
oxidative to glycolytic metabolism in TH17 cells and M1
macrophages101. Yet another example is kynurenine, a tryptophan
metabolite generated by indoleamine 2,3-dioxygenase (IDO),
expressed by dendritic, Treg and endothelial cells, which
suppresses CTLs and TH1 cells while stimulating TH2 polarization
and Treg cell recruitment102. Finally, glutathione released by dendritic
cells is cleaved to cysteine, which promotes Teff cell proliferation; Treg
cells inhibit this signalling103. Metabolic enzymes also engage in
signalling in immune cells. For instance, GAPDH binds to the 39
untranslated region of cytokine mRNAs (such as IFN-c) and
thereby dampens their expression60. Thus, when GAPDH is not
supporting glycolysis for ATP production in Tcells, it switches
from its role as metabolic enzyme to an RNA-binding
protein, thereby providing a metabolic checkpoint for Tcells
to couple effector status with glycolysis when sufficient
nutrient is available60.
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overgrowth in diabetic retinopathy is stimulated by ischaemia, an angio-
genic stimulus. The retinal ischaemia results from vessel hypoperfusion
caused by multiple vascular anomalies, including vessel disintegration
due to vascular cell death, leakage due to impaired junctional integrity
and bleeding due to rupture of microaneurysms2. Death of these vas-
cular cells occurs as a result of excessive ROS production by an activated
polyol pathway andmitochondrial dysfunction42. Increased glucose flux
through the hexosamine biosynthetic pathway may also be involved,
possibly viaO-linked glycosylation of Akt43. From a clinical perspective,
it is worth noting that glycaemic control reduces micro- but not macro-
vascular complications, suggesting a distinctive role of EC metabolism
in different vascular beds44. Thus, it would be interesting to investigate
whether the metabolism of micro- and macrovascular ECs differ.
Metabolism of healthy fibroblasts
Glycolysis and TCA cycle
Fibroblast metabolism has been studied only to a limited extent, but
available evidence indicates that proliferating fibroblasts produce new
biomass for replication, whereas quiescent fibroblasts generate biomass
to replace oxidized lipids anddegradedproteins, and to synthesizematrix
proteins45. Glycolysis is higher in proliferating fibroblasts than quiescent
fibroblasts, but only by twofold, indicating that quiescent fibroblasts have
high glycolytic needs for baseline homeostasis45 (Fig. 2a, b). Quiescent
and cycling fibroblasts incorporate glucose carbons in the TCA cycle at
comparable rates45. However, compared to proliferating fibroblasts inwhich
glucose and glutaminemetabolism in the TCA cycle is truncated at citrate,
quiescent fibroblasts are able to use a fully operational TCA cycle. Quiescent
and proliferating fibroblasts also differ in anaplerosis, a process that re-
plenishes TCA cycle intermediates. Indeed, in quiescent fibroblasts, ana-
plerotic flux frompyruvate tooxaloacetate viapyruvate carboxylase ensures
continuity of the TCA cycle, whereas proliferating fibroblasts primarily use
glutamine for anaplerosis45. Further, reductive carboxylation of a-KG by
mitochondrial isocitrate dehydrogenase (IDH)-2 is higher in quiescent
fibroblasts, generating lipogenic acetyl-CoA for fatty acid synthesis45
(Fig. 2a, b).
NADPH-producing pathways
Like cancer cells, proliferating fibroblasts rely on the PPP to generate
ribose-5-phosphate andNADPHfor biosynthesis, and incorporate glucose
carbons via this pathway into nucleotides45. By contrast, quiescent fibro-
blasts use thePPP togenerateNADPHfor redoxhomeostasis, withglucose
carbons flowing back to glycolysis as GAP and fructose-6-phosphate45.
Quiescent fibroblasts also produce larger amounts of cytosolic NADPH
by increasing the IDH-1 flux45. The role of the PPP in redox balance is
essential for quiescence, as its inhibition induces apoptosis of quiescent but
not of cycling fibroblasts45.
Metabolism of cancer-associated fibroblasts
Cancer-associated fibroblasts (CAFs) promote the growth andmetastasis
of cancers. A bidirectional crosstalk between cancer cells and CAFs has
been identified, whereby cancer cells highjack CAFs to produce high-
energy nutrients for their own use46. In this crosstalk, production of ROS
by cancer cells induces hypoxia-inducible factor 1a (HIF-1a) in neigh-
bouringCAFs via inhibition of prolyl-hydroxylase domain (PHD)proteins.
By inducing autophagy, HIF-1a promotes the degradation of caveolin-1, a
negative regulator of NO production. Excess production of NO then inhi-
bits cytochrome c oxidase and leads to dysfunctionalmitochondria, which
further elevates ROS levels in CAFs46. As CAFs remove dysfunctional
mitochondria via mitophagy, they rely on enhanced glycolysis, leading
to increased lactate production46. CAFs also generate amino acids and
ketone bodies, which togetherwith lactate are used by cancer cells inmore
oxygenated areas as high-energy nutrients of oxidative metabolism to
generate ATP47,48. Via this metabolite crosstalk, CAFs thus feed nearby
cancer cells. Proliferating CAFs also have increased rates of fatty acid
synthesis, and blocking this process reduces their proliferation49.
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Figure 2 | Fibroblastmetabolism. a, b, Scheme of the characteristicmetabolic
pathways in quiescent and proliferating fibroblasts. a, Quiescent fibroblasts:
(i) have relatively high baseline glycolysis levels (blue). (ii) The PPP (purple) is
important for redox homeostasis through enhanced production of NADPH
(note that glucose carbons in the PPP flow back to glycolysis). (iii) Pyruvate
carboxylase (dark blue) anaplerotically fills the TCA cycle with glucose
carbons for glucose oxidation (orange),whereas (iv) glutamine is an anaplerotic
carbon source for the TCA cycle (green; from glutamine to a-KG). (v) The
TCA cycle proceeds in the forward (clockwise) direction. Quiescent fibroblasts
have a high reductive carboxylation flux (green; from a-KG to citrate in
anticlockwise reverse direction), generating acetyl-CoA for fatty acid synthesis
(red) and NADPH for redox homeostasis by IDH1. Reductive carboxylation
of a-KG, derived from glucose carbons, also occurs. b, Proliferating fibroblasts:
(i) glycolysis (blue) is increased twofold in proliferating fibroblasts.
(ii) The PPP is used to generate nucleotides and other macromolecules.
(iii) Pyruvate carboxylase anaplerotically fills the TCA cycle with glucose
carbons for glucose oxidation (dark blue), but (iv) glutamine is the major
anaplerotic carbon source for the TCA cycle, consuming twice as much
glutamine than quiescent cells (green; from glutamine to a-KG).
(v) Proliferating fibroblasts have a truncated TCA cycle at citrate, preventing
clockwise TCA cycling of glucose and glutamine carbons. However,
compared to quiescent cells, they have a lower reductive carboxylation flux
(green; from a-KG to citrate in the reverse direction anticlockwise),
generating acetyl-CoA for FAS (red) and NADPH for redox homeostasis by
IDH1. Iso, isocitrate; PC, pyruvate carboxylase; other abbreviations as in
Fig. 1.
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Immune cells
The innate immune system provides the first line of defence against
infectionbyorganismsbearingwidely conservedpathogenmotifs,whereas
the adaptive immune system confers long-lasting antigen-specific protect-
ive immunity. The innate immune system is comprised of mast cells,
macrophages, granulocytes (including basophils, eosinophils and neu-
trophils), dendritic cells and natural killer cells, whereas the adaptive
immune system consists of B lymphocytes andT lymphocytes, including
CD41Thelper (TH) cells andCD8
1 cytotoxicT (CTL) cells. These immune
cells contribute to tissuehomeostasis inhealthy conditions, but also influence
tumour progression and metabolic disorders including type 2 diabetes50,51.
We will discuss T cells andmacrophages, for whichmetabolism has been
best characterized.
T-cell metabolism
TheT-cell response to immunogensoccurs in three steps: priming, expan-
sion and contraction. Naive T (Tn) cells are quiescent, but after engage-
ment by an antigen-presenting cell, Tn cells become activated, or primed.
Upon activation of the T-cell receptor (TCR), Tn cells undergo an initial
growth phase (increase in cell size) during the first 24 h, followed by clonal
expansion and differentiation over the next 24–72 h. During activation,
they differentiate into a heterogeneous population of subsets of T effector
(Teff) cells. To divide every 6 to 8 h, and to produce effector molecules,
T cells require increased amounts of energy and precursors for biomass
production.Once the antigen is cleared, theTeff cell population contracts
and 90–95%of the activatedTeff cell pool dies, although a residual 5–10%
ofmemoryT cells (Tm inmice; Tcm (centralmemory) inhumans) survives
and provides immune memory; Tm cells can also differentiate from Tn
cells52. By responding with greater speed and vigour to a repeat encounter
with antigen, Tm cells protect the host without causing overt disease.
Metabolism during T-cell priming and expansion
Tn cells require minimal amounts of energy to prevent atrophy, survive
and patrol the organism for antigen surveillance. Their ATP originates
.90% from FAO and OxPhos, and to a lesser extent from glycolysis53,54
(Fig. 3b). Tn cells also have low levels of glutamine anaplerosis55.
ActivationofT cells induces a coordinated increaseof glucose andamino
acid transporters, andupregulatesglucoseandglutaminecatabolism(Fig.3b).
Indeed, primedT lymphocytes increase glycolysis by 20–50-fold, even in
normoxia56. This increase stems partly from translocation of the glucose
transporter GLUT1 to the plasma membrane and upregulation of gly-
colytic enzymes like hexokinase 2 and ADP-dependent glucokinase56–59.
Glucose consumption by the PPP is also increased, although it is unclear
forwhich purpose54,58. Aside from glycolysis, activatedT cells also oxidize
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Figure 3 | T-cell metabolism. a, b, Metabolism of quiescent naive and
activated T cells. a, (i) Tn cells rely primarily on FAO (red), (ii) baseline
glutamine metabolism (green), (iii) but minimal glycolysis (grey). b, Upon
activation, (i) they increase glucose uptake through GLUT1 and glycolysis by
upregulation of hexokinase 2 (HK2) and ADP-dependent glucokinase
(ADPGK) for ATPproduction. (ii) Increased PPP flux providesmetabolites for
redox homeostasis (NADPH) and proliferation (ribose-5-phosphate).
(iii) Increased uptake of glutamine fuels the TCA cycle via anaplerosis (green),
(iv) while FAO levels are reduced. The TCA proceeds in clockwise direction
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as in Fig. 1.
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glutamine-deriveda-KG60. In addition, theymetabolize glutamine via orni-
thine to mitogenic polyamines to promote their growth58.
T-cell proliferation also relies on enhanced glucose andglutaminemeta-
bolism, and the importance of both pathways is exemplified by findings
that deprivation of each nutrient blocks this process, even if other carbon
sources are available56,58. Although OxPhos can fuel T-cell proliferation60,
increased glucose uptake and glycolysis, not OxPhos, are necessary to
activateCD41 andCD81Tcells to full effector status uponTCRactivation,
an effect relying in part on signalling by the glycolytic enzyme GAPDH in
CD41 T cells60,61 (Box 1). By inducing ROS signalling, OxPhos can also
affect CD81 T-cell expansion62.
Proliferating cells often elevate fatty acid synthesis (see above).Although
oxidation of glutamine-derived a-KG in the TCA cycle is only a minor
source of lipogenic acetyl-CoA in normal conditions (when it is primarily
derived from glucose metabolism), a-KG can be converted to citrate via
reductive carboxylation in conditions of hypoxic stress or mitochondrial
dysfunction63,64. T cells, which often operate in hypoxicwounds or inflamed
tissues, preferentially use glutamine for biosynthesis of lipids by switching
on reductive carboxylation63. In agreement, TCR activation increases fatty
acid synthesis and induces a redistribution of arachidonate from phos-
phatidylcholine to phosphatidylethanolamine species65. Together, this
coordinatedmetabolic switch promotes biosynthesis of proteins, nucleo-
tides and phospholipids for rapid cell proliferation and effector status.
Metabolism during T-cell differentiation
OnceT cells divide, theydifferentiate todifferentT-cell subsets, each switch-
ing on distinctive metabolic pathways. Activated CD41 Tcells differentiate
to subsets of Teff cells: TH1 cells mediate responses to intracellular patho-
gens, TH2 cells control responses tohelminths, andTH17cells are important
in the defence against extracellular bacteria and fungi (Fig. 3c). Teff cells
upregulate glycolysis for anabolic purposes and suppress catabolic FAO
for ATP production66,67 (Fig. 3c). Teff cells also require glutamine for late
effector status68; however, themetabolic fate of glutamineoxidation remains
unknown. Activated CD81 CTLs also upregulate glucose and glutamine
catabolism, but unlike CD41 T cells, they do not increase OxPhos, mak-
ing them more sensitive to glucose depletion53,54.
Immune-suppressive regulatory T (Treg) cells, another differentiated
cell type, rely onFAOforATPproduction67,69. Interestingly, these cells do
not exhibit a sudden proliferation burst like Teff cells, but continuously
proliferate at moderate levels. Whether this might explain their depend-
ence on FAO rather than glycolysis is unknown. Treg cells also differ from
TH17 cells in their need for amino acid metabolism. Indeed, depletion
of extracellular amino acids suppresses TH17 cell differentiation, while
favouring Treg cell development and T-cell anergy (a long-term state of
hyporesponsiveness in response to suboptimal stimulation)70.
Tm cells adopt a metabolic profile comparable to that of Tn cells, but
differ by increased mitochondrial mass and reserve respiratory capacity,
which prepares them for rapid mitochondrial ATP production upon TCR
re-engagement, and provides a bioenergetic advantage upon secondary
antigenexposure71.Hence, specificmetabolicprograms indifferent immune
cells are critical for multiple aspects and during specific phases of the
immune response, with engagement of glycolysis and FAO during acute
and more chronic antigen exposure, respectively.
The metabolic phenotype of activated T cells is influenced by the mi-
croenvironment. Indeed, during graft versus host disease (GVHD), allo-
genic Teff cells increase not only glycolysis but also fatty acid uptake and
FAO to support activation and proliferation in vivo72. Presumably, the
prolonged presentation of antigens to T cells combined with other factors
(for example, the type of antigen-presenting cell) during GVHD drives
these cells to generate ATP as efficiently as possible by using oxidative
metabolism as well (Fig. 3c). This is different from a condition whereby
only limited amounts of antigens are presented for a finite period with
minimal amounts of systemic inflammation, which T cells can handle by
upregulating glycolysis alone. Signalling by metabolites and metabolic
enzymes, and metabolite crosstalk, also regulate T-cell growth, differ-
entiation and function (Box 2).
Macrophage metabolism
M1-like macrophages
Macrophages are terminally differentiated cells that do not need energy
and biomass to proliferate but instead to sustain a high phagocytic and
secretory activity. Macrophages are polarized to distinct phenotypes73.
When activated by interferon (IFN)-c alone or in concert withmicrobial
stimuli (like LPS) or pro-inflammatory cytokines (like tumour necrosis
factor (TNF)-a), they acquire an inflammatory phenotype, and are termed
‘classically activated’M1macrophages. These cells have a highmicrobiocidal
activity, as well as enhanced production of pro-inflammatory cytokines and
ROS. M1 macrophages increase glycolysis by inducing the expression
of the pro-glycolytic PFKFB3 isoform74 (Fig. 4a). Their dependence on
glycolysis rather thanmitochondrial ATP production, even in normoxia,
offers M1 macrophages energetic advantages in hypoxic regions75.
LPS has various effects on macrophage metabolism: first, it increases
levels of the TCA intermediate succinate, which upregulates IL-1b express-
ion via activation of HIF-1a (succinate inhibits PHDs that negatively regu-
late HIF-1a)76. Second, it increases succinylation ofmetabolic proteins, but
the precise function of this modification remains unknown76. Third, LPS
increases the expression of immunoresponsive gene 1 (IRG1), an enzyme
producing itaconic acid77 (Fig. 4a). Because itaconic acid inhibits isocitrate
lyase, the key enzyme of the glyoxylate shunt in pathogens, this metabolite
exerts antimicrobial activity during bacterial infections77.
A key feature ofM1macrophages is their ability to produce high levels
of mitochondrial ROS to kill phagocytosed bacteria. IRG1 enhances FAO
andOxPhos togeneratebactericidalmitochondrialROS insidephagosomes
containing ingested bacteria78 (Fig. 4a). M1 macrophages also release ROS
andreactivenitrogen species (includingNO) inphagosomes forkillingpath-
ogens. ROSandNOfor this purpose are generatedbyNADPHoxidase and
inducible nitric oxide synthase (iNOS), respectively (Fig. 4a). Both enzymes
requireNADPH,which is produced in thePPPaswell as bymalic enzyme.
The latter NADPH-producing mechanism is induced in response to LPS.
In brief, LPS increases transport of mitochondrial citrate to the cytosol,
where it is converted tooxaloacetate and then topyruvate bymalic enzyme,
thereby generating NADPH79. To protect themselves against ROS leaking
into the cytosol during suchhighoxidative burst,M1macrophages also use
NADPHfromthePPP for theproductionof the antioxidantGSH(Fig. 4b).
To phagocytose, a large turnover of lipids and generation ofmembrane-
rich filopodia and organelles are required. Macrophages therefore increase
phospholipid synthesis and switch fromcholesterol to phosphatidylcholine
BOX 2
Metabolite crosstalks
Metabolite exchange between stromal and parenchymal cells is
common and essential for the function of numerous tissues. For
instance, extracellular lactateproducedbyECs functions asadynamic
vasoactivesignal forpericytes. Indeed,whencellularenergyavailability
is low, lactate causes vasodilation to promote fuel supply, but when
energy supplies are abundant, lactate acts as a vasoconstrictor104. This
glycolytic metabolite, produced by cancer cells, also promotes
angiogenesis, inhibits cytotoxic T-cell responses, and causes chronic
inflammation through enhanced IL-17A secretion, which activates
TH17 cells102. As Teff cells consume glucose intensely during early
inflammation, glucose deprivation might promote Treg cell
differentiation to dampen inflammation67. Further, acidification of the
tumour microenvironment by lactate increases arginase 1 levels in
macrophages, which limits the anti-tumour immune response (see
text)105. This effect canbeabrogatedby the glucose oxidation inhibitor
dichloroacetate105. An analogous metabolic cooperation exists
between cancer-activated adipocytes and cancer cells, where cancer
cells reprogram themetabolismof adipocytes to becomecatabolic, so
that they release fatty acids as fuel for cancer cells106.
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production80. The importance of fatty acid synthesis is revealed by findings
that its suppression prevents phagocytosis80. Citrate is alsometabolized for
the synthesis of phospholipids, a source of arachidonic acid for the pro-
duction of pro-inflammatory prostaglandin79.
M2-like macrophages
‘Alternatively activated’M2macrophages are associatedwith tissue repair,
angiogenesis and pro-allergic and anti-parasitic TH2 immunity, as well as
with anti-inflammatory cytokine production and reduced expression of
major histocompatibility complex class II and antigen presentation73. They
have low glycolysis rates and no detectable PFKFB3 levels, expressing the
weak glycolytic activator PFKFB1 instead, but have high rates of FAO and
OxPhos81 (Fig. 4b). The M2-macrophage-inducing signal IL-4 stimulates
mitochondrial biogenesis by upregulating PGC-1b, thereby enhancing a
metabolic switch to FAO82. Also, by stimulating angiogenesis and tissue
oxygenation, M2macrophages prepare for oxidative metabolism. Of note,
a high lipid content, as occurs upon impairment of cholesterol efflux, pro-
motes the angiogenicM2phenotype83, further establishing the link between
lipidmetabolism andM2polarization. Thus, theM2macrophage secretory
program is energetically demanding, both in termsof intensity andduration,
andoxidativemetabolism isbest suited tomeet thebioenergetic demands for
long-term macrophage activation.
M2 macrophages decrease the PPP flux and GSH levels via upregula-
tion of carbohydrate kinase-like protein (CARKL, also known as SHPK).
This kinase lowers the oxidative PPP flux by catalysing the formation
of sedoheptulose-7-phosphate, a PPP inhibitor84 (Fig. 4b). It has been
proposed thatM2macrophages decrease the PPP flux, because the activ-
ity of key inflammatory regulatorsmight be sensitive to the redox state84.
Overall, it is becoming increasingly evident that intracellular metabolic
changes are necessary to determine the activation status and function of
macrophages, but also that macrophages can alter metabolic functions
of other cells in the environment (Box 2)85.
Macrophage metabolism in cancer
Tumours harbour distinct types of tumour-associated macrophages (TAMs),
that is,M1TAMs suppressing andM2TAMspromoting tumour growth73.
Little is known about specific metabolic adaptations of TAMs. They differ,
however, in their use of arginine. Indeed, M1 TAMs express iNOS, which
converts arginine toNO, which is cytotoxic for tumour cells86 (Fig. 4a). By
contrast, M2 TAMs express arginase 1, which metabolizes arginine to
ornithine (a precursor of polyamines), which promotes M2 polarization
and can stimulate nearby cancer cells86 (Fig. 4b). By upregulating arginase
1,M2TAMs impair the anti-tumour activity of T cells as this depletes the
arginine pool for NO and protein synthesis, which impairs TCR function87.
However, the role of arginases in polyamine production in macrophages
requires further study, as polyamines can be generated in their absence.
Metabolism determines cell differentiation
Cancer cellmetabolism studies have focused onunderstanding howmalig-
nant cells adopt their metabolism to sustain increased proliferation rates.
Emergingevidence fromstudyingnon-transformedendothelial and immune
cells now shows thatmetabolism not only supports cell proliferation, but
also seems to be a determinant of cell differentiation. Nonetheless, unrav-
ellingwhether themetabolic signature of differentiatedcell types is simply a
consequence of lineage/phenotype-specific signalling or rather is instruc-
tive for regulating cell plasticity and/or function remains a question for the
field.
Endothelial cells
Vascular sprouting relies on collective ECmigration,whereby the leading
endothelial tip cell at the vascular front guides the sprout and trailingprolif-
erating stalk cells elongate the sprout1. As the pro-tip cell signal VEGF ele-
vatesPFKFB3expression,PFKFB3 levels arehigher in tip than in stalk cells10
(Fig. 1a inset). PFKFB3 overexpression is capable of overruling Notch
signalling, thereby empowering stalk cells to become tip cells10. This is
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GSSG, oxidized glutathione; GSH, reduced glutathione; iNOS, inducible nitric
oxide synthase; PFKFB1, 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-1; other abbreviations as in Fig. 1.
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remarkable, as Notch is the most potent pro-stalk signal known to date.
Thus, PFKFB3-driven glycolysis regulates the plasticity of ECphenotypes,
and not only genetic but also metabolic signals regulate vessel sprouting.
Immune cells
Metabolism also controls T-cell lineage choices. In accordance with the
importance of glycolysis for Teff cells, activation of glycolysis by transgenic
expression ofGLUT1or glycolytic genes augmentsT-cell activation, results
in the accumulation of readily activated Tm-like cells with signs of auto-
immunity in aged mice56, and drives CD81 T cells towards a terminally
differentiated, more short-lived state88. Conversely, blocking glycolysis
via pharmacological or transgenicmeans impairs TH17 cell proliferation
and differentiation while promoting Treg cells, thereby protecting mice
from autoimmune inflammation58,66. Moreover, inhibiting glucose meta-
bolismpreserves the formationof long-livedCD81Tmcells in vivo88, while
rendering T cells anergic54.
Amino acid and fatty acidmetabolism are also important, as inhibition
of glutaminase impairs Teff-cell proliferation58, whereas FAO blockade
inhibits Treg differentiation67 and the survival of alloreactive T cells72.
Conversely, the short-chain fatty acid butyrate, produced by commensal
microorganisms, promotes Treg-cell development in the colon, thereby
protectingmice against colitis89–91. Also, bymediating leucine uptake, the
amino acid transporter SLC7A5 induces CD41 and CD81 T-cell differ-
entiation via activation of mammalian target of rapamycin complex 1
(mTORC1), glycolysis and glutamine metabolism, thereby functioning
as ametabolic checkpoint92.Macrophage differentiation is also determined
by metabolism. Indeed, pretreatment of macrophage precursors with res-
piration or FAO blockers abrogates M2 activation, without affecting the
M1 phenotype81. Aside from a role in metabolism, metabolites and meta-
bolic enzymes modulate the plasticity of immune cells by affecting gene
transcription, signalling pathways or epigenetic programs (Box 2).
Metabolic commonalities and differences
This overview highlights that ECs, fibroblasts and immune cells both
share and differ in their use of metabolic pathways, although metabolism
is incompletely characterized in some of these cell types. For instance,
proliferating endothelial stalk cells, fibroblasts, TH1 cells, TH2 cells and
TH17 cells all rely on increased glycolysis, glutaminemetabolism and fatty
acid synthesis to generate the needed amount ofATP andnewbiomass for
cell division. Endothelial tip cells, Teff cells and activatedM1macrophages
also rely on glycolysis, but use it instead to achieve full effector status. By
contrast, Tm cells, Treg cells, alloreactive T cells andM2macrophages rely
primarily on FAO to generate ATP more efficiently. Oxidative metabol-
ism seems to be best suited tomeet the bioenergetic demands for the long-
termperformance of these cells. Reductive carboxylation ofa-KG for fatty
acid synthesis has only been identified to date in M1 macrophages and
fibroblasts, but is probably also relevant for other non-transformed cell
types.
ThePPP is of vital importance formany cells, but is used for distinctive
purposes in different stromal and immune cell types. For instance, the
PPP is essential for biosynthesis ofmacromolecules in proliferating fibro-
blasts and probably also in other dividing cells (ECs, T cells), although
evidence is lacking so far. The PPP and other NADPH-generating path-
ways (including FAO) are used byM1macrophages for the production of
ROS to kill pathogens. To buffer this oxidative burst, they must also use
the PPP for redox homeostasis. Quiescent fibroblasts are unusually sens-
itive to redox balance offered by the PPP. ROS have a signalling role in
ECs and T cells, unlike their lethal bactericidal effects inM1macrophages.
Quiescent ECs and fibroblasts differ from Tn cells in their needs for
glycolysis during homeostatic maintenance. This may relate to the fact
that quiescent Tn cells are largely inactive, awaiting activation by foreign
antigen, whereas quiescent ECs and fibroblasts must continuously main-
tain the vascular barrier, transport molecules, synthesize matrix, replen-
ish degradedmacromolecules andperformhomeostatic activities. Unlike
other stromal and immune cells,macrophages do not usemetabolism for
division, but to resynthesize degraded biomass and achieve full effector
status. Overall, stromal and immune cells have adopted theirmetabolism
to optimally fulfil their distinctive role as support cells in particular con-
ditions, in which each of these stromal and immune cells must fulfil
specialized functions.
Outstanding questions and perspectives
We suspect that the studies discussed here merely scratch the surface
of themetabolic control of stromal and immune cells.Multiple questions
require an answer in the future. A priority for EC and fibroblast metabol-
ism research is to establish a road map of additional metabolic pathways
that have not been studied to date. It will be equally fruitful to study how
stromal and immune cell types metabolically communicate with each
other and other (cancer) cells, and whether pathways or signalling prop-
erties of metabolic enzymes, characterized in cancer cells, also exist in
stromal and immune cells. Analysing the metabolism of these cell types
in vivo, in preclinical animal models and ultimately in patients is an im-
portant yet challenging translational priority for the future. Furthermore,
little is known about the metabolism of various stromal cell types (for
example, arterial, venous, lymphatic or tumourECs; pericytes and smooth
muscle cells; bone marrow mesenchymal cells, hepatic stellate cells) and
other immune cells (for example, neutrophils, basophils, monocytes, den-
dritic cells) or of their progenitors, and whether metabolism determines
their phenotypic identity. For instance, do tip and stalk ECs have distinct
metabolic signatures (besides a difference in glycolysis), and do pro-tip or
pro-stalk cell signals determine specific metabolic pathways?
Another question is whether stromal and immune cell metabolism
differs from cancer cell metabolism. It has been postulated that the unique
propertiesof cancer cellmetabolismwouldoffer opportunities to selectively
target cancer cells. Although this seems plausible for tumours in which
metabolism is changedby genetic alteration or overexpression ofmetabolic
targets, it is unknown whether blocking metabolic changes more com-
monly seen in other tumours will target cancer cells selectively. Although
metabolic similarities in cancer and stromal/immune cells may enhance
anti-cancer therapies targeting a common metabolic pathway, possible
consequences on healthy stromal cells, which also rely on these pathways,
will need to be evaluated.
Finally, what are the translational consequences of these insights into
stromal and immune cellmetabolism formalignant,metabolic or inflam-
matory disease?Will it be possible to target particular stromal or immune
cells, and targetonlyactivatedorproliferatingcellswithoutaffectingquiescent
cells? Reports that blocking glycolysis protects mice from autoimmune
inflammation by impairingTH17 cell proliferation anddifferentiation,while
favouring Treg cell differentiation, suggest that this might be possible58,66.
Another example is the transient and partial reduction of glycolysis by
PFKFB3 blockade, which is sufficient to reduce pathological angiogen-
esis, without affecting pre-established vessels or evoking overt toxicity or
metabolic compensation14.
In preclinical models, lowering glycolysis improves psoriasis93, protects
against autoimmune inflammation58,66, reduces ocular neovascularization
(a common complication in diabetics)14 and decreases tumour growth by
inhibiting the growth of cancer cells and probably of ECs, fibroblasts and
T cells94. In addition, glycolytic blockade enhances the anti-angiogenic
effect of VEGF inhibitors, indicating that targeting metabolism can am-
plify available treatments14. The preclinical finding that inhibition of AR
improves vascular complications in diabetes95 has been translated to the
clinical situation, and treatment of humandiabeticswith theAR inhibitor
epalrestat prevents further progression of retinopathy96. These examples
illustrate the therapeutic potential of targetingmetabolism in stromal and
immune cells, and should provide an incentive to further characterize
metabolism in these cells.
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